AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Trailhead Biosystems Raises $10 Million To Accelerate Growth

Oct 11, 2022•almost 3 years ago

Amount Raised

$10 Million

ClevelandBiotechnology

Description

Trailhead Biosystems Inc. (www.trailbio.com) - a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology - announced completion of a $10 million Series A-2 equity financing. The company has developed revolutionary platform for generating specialized human cells for use in therapeutic cell development, drug discovery, organ-on-a-chip development, 3D organ printing, and human disease modeling.

Company Information

Company

Trailhead Biosystems

Location

10000 Cedar Avenue

Cleveland, Ohio, United States

About

Trailhead Biosystems merges developmental biology and cell therapeutics with cutting edge hardware, and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design (QbD) principles, cell culture optimization is done by utilizing Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows Trailhead to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. DoE-based experimental design and robotic execution greatly reduce the number of experiments and time needed for optimizing a large number of variables simultaneously.

Company News

(3 articles)

Tue, 05 Aug 2025 09:00:00 GMT

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells - PR Newswire UK

Wed, 23 Jul 2025 07:00:00 GMT

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons - PR Newswire

Tue, 20 May 2025 07:00:00 GMT

Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer - PR Newswire

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech